BioSpace News Archive

mHTT results from PRECISION-HD trials do not support further development of WVE-120102 and WVE-120101 No observed change in wtHTT and NfL during trials Advancing Phase 1b/2a trial for WVE-003 (SNP3) program in HD; WVE-003 uses new PN backbone chemistry modifications, which demonstrate improved preclinical pharmacology

Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced the closing of its previously announced underwritten public offering of 17,142,857 shares of its common stock at $1.75 per share. Evofem’s aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses

Q4 features revenues of $18.5 million; 2020 revenues reach $27.5 million driven by COVID-19 testing Introduces strategy to establish proprietary CSF assay as the standard of care in detecting cancer that has metastasized to the brain or central nervous system Conference call begins at 4:30 p.m. Eastern time today

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced a collaboration with MapKure, LLC, a clinical-stage company focusing on genetically defined disease drivers and jointly owned by BeiGene, Ltd. and SpringWorks Therapeutics, Inc., to use a clinical trial assay (CTA) based on the Personalis ® NeXT Platform™

- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of 2,500,000 shares of its common stock. All of the shares in the proposed offering will be sold by AMT.

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the appointment of Ms. Kim Nguyen and Mr. Richard Brudnick to the Company’s Board

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, have established Automatic Securities Disposition Plans (“ASDPs”) in accordance with applicable United States and Canadian securities legislation, including U.S. Securities and Exchange Commission

Total revenue of $233 million 1 in 2020, up 1,908% year-over-year Total revenue from research fees of $20 million, up 71% year-over-year Total programs under contract of 103, up 72% year-over-year EPS of $0.53 (basic) and $0.45 (diluted) compared to $0.01 loss per share in 2019

Merck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application (sBLA) for KEYTRUDA ® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)

At the Experimental Nuclear Magnetic Resonance Conference 2021 (ENC), Bruker Corporation (Nasdaq: BRKR) announces that the Forschungszentrum Juelich (FZJ), Germany has expanded its research into functional structural biology in neurodegenerative diseases with the addition of a 1.2 GHz Avance™ nuclear magnetic resonance (NMR) spectrometer